The B cell in systemic lupus erythaematosus: a rational target for more effective therapy
Identifieur interne : 001200 ( Istex/Corpus ); précédent : 001199; suivant : 001201The B cell in systemic lupus erythaematosus: a rational target for more effective therapy
Auteurs : C B Driver ; M. Ishimori ; M H WeismanSource :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2008-10.
English descriptors
- Teeft :
- Abetimus, Abetimus sodium, American college, Animal models, Antibody, Antibody production, Antibody titres, Antimalarial agents, Arthritis, Arthritis rheum, Arthritis rheum leandro, Autoantibody, Autoantibody levels, Autoantibody production, Autoimmune disease, Autoimmune diseases, Baff, Baff costimulation, Baff receptor, Baff receptors, Belimumab, Cell abnormalities, Cell activation, Cell defects, Cell depletion, Cell dysfunction, Cell function, Cell hyperactivity, Cell levels, Cell maturation antigen, Cell migration, Cell numbers, Cell proliferation, Cell receptor, Cell subpopulations, Cell surface molecules, Cell survival, Cell therapy, Cell tolerance, Cell tolerance checkpoints, Clin, Clinical data, Clinical efficacy, Clinical trials, Costimulatory, Costimulatory molecules, Ctla4ig, Curr opin rheumatol looney, Cyclophosphamide, Dendritic cells, Dihydroorotate dehydrogenase, Disease activity, Epratuzumab, Erythaematosus, Erythematosus, Furie, High expression, Humanised antibody, Immunol, Intravenous cyclophosphamide, Investigational therapies, Ligand, Longitudinal analysis, Lupus, Lupus erythematosus, Lupus erythematosus patients, Lupus manifestations, Lupus nephritis, Lymphocyte, Monoclonal antibody, Murine, Murine lupus, Murine lupus nephritis, Mycophenolate mofetil, Nephritis, Other agents, Ovarian failure, Pathogenic antibodies, Peripheral blood, Peripheral blood lymphocytes, Plasma cells, Preliminary results, Rational target, Receptor, Renal, Renal disease, Renal failure, Renal flare, Renal flares, Rheum, Rheumatoid arthritis, Rheumatol, Rheumatology, Rituximab, Rituximab therapy, Serious toxicity, Significant reduction, Systemic, Systemic lupus erythaematosus, Systemic lupus erythematosus, Systemic lupus erythematosus patients, Target organs, Thromboembolic events, Transmembrane activator.
Abstract
Current treatment options for systemic lupus erythaematosus (SLE) are diverse and poorly defined, and aggressive therapy can be associated with serious toxicity and tolerability issues. There is, therefore, a need for new and improved treatments to be studied thoroughly in well-designed controlled trials. B Cell dysfunction has emerged as a key pathophysiological component of SLE and is a prime target for the development of new agents for a wide range of lupus severity, including advanced disease. Although many current drugs appear to modify B cell function, the advent of new, targeted therapies offers the hope of improved efficacy and a better long-term tolerability profile.
Url:
DOI: 10.1136/ard.2007.076745
Links to Exploration step
ISTEX:ECFC78EBE021338B8A8F536C827BFF4FCD7B5CBELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The B cell in systemic lupus erythaematosus: a rational target for more effective therapy</title><author><name sortKey="Driver, C B" sort="Driver, C B" uniqKey="Driver C" first="C B" last="Driver">C B Driver</name><affiliation><mods:affiliation>Cedars-Sinai Medical Center, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Ishimori, M" sort="Ishimori, M" uniqKey="Ishimori M" first="M" last="Ishimori">M. Ishimori</name><affiliation><mods:affiliation>Cedars-Sinai Medical Center, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Weisman, M H" sort="Weisman, M H" uniqKey="Weisman M" first="M H" last="Weisman">M H Weisman</name><affiliation><mods:affiliation>Cedars-Sinai Medical Center, Los Angeles, California, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:ECFC78EBE021338B8A8F536C827BFF4FCD7B5CBE</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1136/ard.2007.076745</idno><idno type="url">https://api.istex.fr/ark:/67375/NVC-1M8N6Z0Q-5/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001200</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001200</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The B cell in systemic lupus erythaematosus: a rational target for more effective therapy</title><author><name sortKey="Driver, C B" sort="Driver, C B" uniqKey="Driver C" first="C B" last="Driver">C B Driver</name><affiliation><mods:affiliation>Cedars-Sinai Medical Center, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Ishimori, M" sort="Ishimori, M" uniqKey="Ishimori M" first="M" last="Ishimori">M. Ishimori</name><affiliation><mods:affiliation>Cedars-Sinai Medical Center, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Weisman, M H" sort="Weisman, M H" uniqKey="Weisman M" first="M H" last="Weisman">M H Weisman</name><affiliation><mods:affiliation>Cedars-Sinai Medical Center, Los Angeles, California, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2008-10">2008-10</date><biblScope unit="volume">67</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1374">1374</biblScope></imprint><idno type="ISSN">0003-4967</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0003-4967</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Abetimus</term><term>Abetimus sodium</term><term>American college</term><term>Animal models</term><term>Antibody</term><term>Antibody production</term><term>Antibody titres</term><term>Antimalarial agents</term><term>Arthritis</term><term>Arthritis rheum</term><term>Arthritis rheum leandro</term><term>Autoantibody</term><term>Autoantibody levels</term><term>Autoantibody production</term><term>Autoimmune disease</term><term>Autoimmune diseases</term><term>Baff</term><term>Baff costimulation</term><term>Baff receptor</term><term>Baff receptors</term><term>Belimumab</term><term>Cell abnormalities</term><term>Cell activation</term><term>Cell defects</term><term>Cell depletion</term><term>Cell dysfunction</term><term>Cell function</term><term>Cell hyperactivity</term><term>Cell levels</term><term>Cell maturation antigen</term><term>Cell migration</term><term>Cell numbers</term><term>Cell proliferation</term><term>Cell receptor</term><term>Cell subpopulations</term><term>Cell surface molecules</term><term>Cell survival</term><term>Cell therapy</term><term>Cell tolerance</term><term>Cell tolerance checkpoints</term><term>Clin</term><term>Clinical data</term><term>Clinical efficacy</term><term>Clinical trials</term><term>Costimulatory</term><term>Costimulatory molecules</term><term>Ctla4ig</term><term>Curr opin rheumatol looney</term><term>Cyclophosphamide</term><term>Dendritic cells</term><term>Dihydroorotate dehydrogenase</term><term>Disease activity</term><term>Epratuzumab</term><term>Erythaematosus</term><term>Erythematosus</term><term>Furie</term><term>High expression</term><term>Humanised antibody</term><term>Immunol</term><term>Intravenous cyclophosphamide</term><term>Investigational therapies</term><term>Ligand</term><term>Longitudinal analysis</term><term>Lupus</term><term>Lupus erythematosus</term><term>Lupus erythematosus patients</term><term>Lupus manifestations</term><term>Lupus nephritis</term><term>Lymphocyte</term><term>Monoclonal antibody</term><term>Murine</term><term>Murine lupus</term><term>Murine lupus nephritis</term><term>Mycophenolate mofetil</term><term>Nephritis</term><term>Other agents</term><term>Ovarian failure</term><term>Pathogenic antibodies</term><term>Peripheral blood</term><term>Peripheral blood lymphocytes</term><term>Plasma cells</term><term>Preliminary results</term><term>Rational target</term><term>Receptor</term><term>Renal</term><term>Renal disease</term><term>Renal failure</term><term>Renal flare</term><term>Renal flares</term><term>Rheum</term><term>Rheumatoid arthritis</term><term>Rheumatol</term><term>Rheumatology</term><term>Rituximab</term><term>Rituximab therapy</term><term>Serious toxicity</term><term>Significant reduction</term><term>Systemic</term><term>Systemic lupus erythaematosus</term><term>Systemic lupus erythematosus</term><term>Systemic lupus erythematosus patients</term><term>Target organs</term><term>Thromboembolic events</term><term>Transmembrane activator</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Current treatment options for systemic lupus erythaematosus (SLE) are diverse and poorly defined, and aggressive therapy can be associated with serious toxicity and tolerability issues. There is, therefore, a need for new and improved treatments to be studied thoroughly in well-designed controlled trials. B Cell dysfunction has emerged as a key pathophysiological component of SLE and is a prime target for the development of new agents for a wide range of lupus severity, including advanced disease. Although many current drugs appear to modify B cell function, the advent of new, targeted therapies offers the hope of improved efficacy and a better long-term tolerability profile.</div></front></TEI><istex><corpusName>bmj</corpusName><keywords><teeft><json:string>lupus</json:string><json:string>erythematosus</json:string><json:string>rituximab</json:string><json:string>systemic lupus erythematosus</json:string><json:string>baff</json:string><json:string>receptor</json:string><json:string>cyclophosphamide</json:string><json:string>rheum</json:string><json:string>immunol</json:string><json:string>lymphocyte</json:string><json:string>autoantibody</json:string><json:string>nephritis</json:string><json:string>ctla4ig</json:string><json:string>murine</json:string><json:string>rheumatology</json:string><json:string>rheumatol</json:string><json:string>cell function</json:string><json:string>epratuzumab</json:string><json:string>costimulatory</json:string><json:string>lupus erythematosus</json:string><json:string>clin</json:string><json:string>abetimus</json:string><json:string>lupus nephritis</json:string><json:string>systemic</json:string><json:string>renal</json:string><json:string>furie</json:string><json:string>belimumab</json:string><json:string>cell depletion</json:string><json:string>erythaematosus</json:string><json:string>ligand</json:string><json:string>arthritis</json:string><json:string>rheumatoid arthritis</json:string><json:string>arthritis rheum</json:string><json:string>systemic lupus erythaematosus</json:string><json:string>cell activation</json:string><json:string>cell abnormalities</json:string><json:string>plasma cells</json:string><json:string>animal models</json:string><json:string>renal flare</json:string><json:string>autoimmune diseases</json:string><json:string>baff receptors</json:string><json:string>peripheral blood</json:string><json:string>significant reduction</json:string><json:string>renal disease</json:string><json:string>cell tolerance</json:string><json:string>target organs</json:string><json:string>abetimus sodium</json:string><json:string>transmembrane activator</json:string><json:string>cell subpopulations</json:string><json:string>costimulatory molecules</json:string><json:string>clinical trials</json:string><json:string>rituximab therapy</json:string><json:string>systemic lupus erythematosus patients</json:string><json:string>cell dysfunction</json:string><json:string>cell surface molecules</json:string><json:string>investigational therapies</json:string><json:string>disease activity</json:string><json:string>cell defects</json:string><json:string>clinical efficacy</json:string><json:string>clinical data</json:string><json:string>other agents</json:string><json:string>lupus manifestations</json:string><json:string>cell maturation antigen</json:string><json:string>antibody production</json:string><json:string>baff receptor</json:string><json:string>dendritic cells</json:string><json:string>cell migration</json:string><json:string>thromboembolic events</json:string><json:string>serious toxicity</json:string><json:string>autoantibody levels</json:string><json:string>baff costimulation</json:string><json:string>rational target</json:string><json:string>cell receptor</json:string><json:string>cell tolerance checkpoints</json:string><json:string>american college</json:string><json:string>pathogenic antibodies</json:string><json:string>high expression</json:string><json:string>cell hyperactivity</json:string><json:string>humanised antibody</json:string><json:string>cell levels</json:string><json:string>renal flares</json:string><json:string>cell therapy</json:string><json:string>cell proliferation</json:string><json:string>renal failure</json:string><json:string>autoantibody production</json:string><json:string>dihydroorotate dehydrogenase</json:string><json:string>ovarian failure</json:string><json:string>murine lupus nephritis</json:string><json:string>intravenous cyclophosphamide</json:string><json:string>longitudinal analysis</json:string><json:string>lupus erythematosus patients</json:string><json:string>cell numbers</json:string><json:string>curr opin rheumatol looney</json:string><json:string>monoclonal antibody</json:string><json:string>autoimmune disease</json:string><json:string>preliminary results</json:string><json:string>murine lupus</json:string><json:string>peripheral blood lymphocytes</json:string><json:string>mycophenolate mofetil</json:string><json:string>arthritis rheum leandro</json:string><json:string>antibody titres</json:string><json:string>cell survival</json:string><json:string>antimalarial agents</json:string><json:string>antibody</json:string></teeft></keywords><author><json:item><name>C B Driver</name><affiliations><json:string>Cedars-Sinai Medical Center, Los Angeles, California, USA</json:string></affiliations></json:item><json:item><name>M Ishimori</name><affiliations><json:string>Cedars-Sinai Medical Center, Los Angeles, California, USA</json:string></affiliations></json:item><json:item><name>M H Weisman</name><affiliations><json:string>Cedars-Sinai Medical Center, Los Angeles, California, USA</json:string></affiliations></json:item></author><articleId><json:string>ar76745</json:string></articleId><arkIstex>ark:/67375/NVC-1M8N6Z0Q-5</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>research-article</json:string></originalGenre><abstract>Current treatment options for systemic lupus erythaematosus (SLE) are diverse and poorly defined, and aggressive therapy can be associated with serious toxicity and tolerability issues. There is, therefore, a need for new and improved treatments to be studied thoroughly in well-designed controlled trials. B Cell dysfunction has emerged as a key pathophysiological component of SLE and is a prime target for the development of new agents for a wide range of lupus severity, including advanced disease. Although many current drugs appear to modify B cell function, the advent of new, targeted therapies offers the hope of improved efficacy and a better long-term tolerability profile.</abstract><qualityIndicators><score>8.248</score><pdfWordCount>7549</pdfWordCount><pdfCharCount>50193</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>8</pdfPageCount><pdfPageSize>595.276 x 793.701 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>104</abstractWordCount><abstractCharCount>684</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>The B cell in systemic lupus erythaematosus: a rational target for more effective therapy</title><pmid><json:string>17720723</json:string></pmid><genre><json:string>research-article</json:string></genre><host><title>Annals of the Rheumatic Diseases</title><language><json:string>unknown</json:string></language><issn><json:string>0003-4967</json:string></issn><eissn><json:string>1468-2060</json:string></eissn><publisherId><json:string>ard</json:string></publisherId><volume>67</volume><issue>10</issue><pages><first>1374</first></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2007-08-24</json:string></date><geogName></geogName><orgName><json:string>SELENA</json:string><json:string>Lupus Erythaematosus – National Assessment</json:string><json:string>Genentech, Inc.</json:string><json:string>Division of Rheumatology</json:string><json:string>ACR</json:string><json:string>US Food and Drug</json:string><json:string>American College of Rheumatology</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Ann Rheum</json:string></persName><placeName></placeName><ref_url></ref_url><ref_bibl><json:string>Cedars-Sinai Medical Center, 8700</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/NVC-1M8N6Z0Q-5</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - rheumatology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - arthritis & rheumatology</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - General Biochemistry, Genetics and Molecular Biology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Immunology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Immunology and Allergy</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Rheumatology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2008</publicationDate><copyrightDate>2008</copyrightDate><doi><json:string>10.1136/ard.2007.076745</json:string></doi><id>ECFC78EBE021338B8A8F536C827BFF4FCD7B5CBE</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-1M8N6Z0Q-5/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-1M8N6Z0Q-5/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/NVC-1M8N6Z0Q-5/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">The B cell in systemic lupus erythaematosus: a rational target for more effective therapy</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://publisher-list.data.istex.fr">BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><availability><licence><p>2008 BMJ Publishing Group and European League Against Rheumatism</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</p></availability><date>2007-08-24</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">The B cell in systemic lupus erythaematosus: a rational target for more effective therapy</title><author xml:id="author-0000"><persName><forename type="first">C B</forename><surname>Driver</surname></persName><affiliation>Cedars-Sinai Medical Center, Los Angeles, California, USA</affiliation></author><author xml:id="author-0001"><persName><forename type="first">M</forename><surname>Ishimori</surname></persName><affiliation>Cedars-Sinai Medical Center, Los Angeles, California, USA</affiliation></author><author xml:id="author-0002"><persName><forename type="first">M H</forename><surname>Weisman</surname></persName><affiliation>Cedars-Sinai Medical Center, Los Angeles, California, USA</affiliation></author><idno type="istex">ECFC78EBE021338B8A8F536C827BFF4FCD7B5CBE</idno><idno type="ark">ark:/67375/NVC-1M8N6Z0Q-5</idno><idno type="DOI">10.1136/ard.2007.076745</idno><idno type="href">annrheumdis-67-1374.pdf</idno><idno type="article-id">ar76745</idno><idno type="PMID">17720723</idno><idno type="local">annrheumdis;67/10/1374</idno></analytic><monogr><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="pISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><idno type="publisher-id">ard</idno><idno type="PublisherID-hwp">annrheumdis</idno><idno type="PublisherID-nlm-ta">Ann Rheum Dis</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2008-10"></date><biblScope unit="volume">67</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1374">1374</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007-08-24</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Current treatment options for systemic lupus erythaematosus (SLE) are diverse and poorly defined, and aggressive therapy can be associated with serious toxicity and tolerability issues. There is, therefore, a need for new and improved treatments to be studied thoroughly in well-designed controlled trials. B Cell dysfunction has emerged as a key pathophysiological component of SLE and is a prime target for the development of new agents for a wide range of lupus severity, including advanced disease. Although many current drugs appear to modify B cell function, the advent of new, targeted therapies offers the hope of improved efficacy and a better long-term tolerability profile.</p></abstract></profileDesc><revisionDesc><change when="2007-08-24">Created</change><change when="2008-10">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-1M8N6Z0Q-5/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus bmj" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="no"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" URI="archivearticle.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="hwp">annrheumdis</journal-id><journal-id journal-id-type="nlm-ta">Ann Rheum Dis</journal-id><journal-id journal-id-type="publisher-id">ard</journal-id><journal-title>Annals of the Rheumatic Diseases</journal-title><abbrev-journal-title abbrev-type="publisher">Ann Rheum Dis</abbrev-journal-title><issn pub-type="ppub">0003-4967</issn><issn pub-type="epub">1468-2060</issn><publisher><publisher-name>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">ar76745</article-id><article-id pub-id-type="doi">10.1136/ard.2007.076745</article-id><article-id pub-id-type="other">annrheumdis;67/10/1374</article-id><article-id pub-id-type="other">annrheumdis;ard.2007.076745</article-id><article-id pub-id-type="pmid">17720723</article-id><article-id pub-id-type="other">1374</article-id><article-id pub-id-type="other">ard.2007.076745</article-id><article-categories><subj-group subj-group-type="heading"><subject content-type="original">Reviews</subject></subj-group></article-categories><title-group><article-title>The B cell in systemic lupus erythaematosus: a rational target for more effective therapy</article-title><alt-title alt-title-type="running-head">Review</alt-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Driver</surname><given-names>C B</given-names></name></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ishimori</surname><given-names>M</given-names></name></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Weisman</surname><given-names>M H</given-names></name></contrib></contrib-group><aff> <addr-line>Cedars-Sinai Medical Center, Los Angeles, California, USA</addr-line> </aff><author-notes><corresp>Dr M H Weisman, Division of Rheumatology, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, California 90048, USA; <email xlink:type="simple">weisman@cshs.org</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2008</year></pub-date><pub-date pub-type="epub-original"><day>24</day><month>8</month><year>2007</year></pub-date><pub-date pub-type="epub"><day>24</day><month>8</month><year>2007</year></pub-date><volume>67</volume><volume-id pub-id-type="other">67</volume-id><volume-id pub-id-type="other">67</volume-id><issue>10</issue><issue-id pub-id-type="other">annrheumdis;67/10</issue-id><issue-id pub-id-type="other">10</issue-id><issue-id pub-id-type="other">67/10</issue-id><fpage>1374</fpage><history><date date-type="accepted"><day>8</day><month>8</month><year>2007</year></date></history><permissions><copyright-statement>2008 BMJ Publishing Group and European League Against Rheumatism</copyright-statement><copyright-year>2008</copyright-year></permissions><self-uri content-type="pdf" xlink:role="full-text" xlink:href="annrheumdis-67-1374.pdf"></self-uri><abstract><p>Current treatment options for systemic lupus erythaematosus (SLE) are diverse and poorly defined, and aggressive therapy can be associated with serious toxicity and tolerability issues. There is, therefore, a need for new and improved treatments to be studied thoroughly in well-designed controlled trials. B Cell dysfunction has emerged as a key pathophysiological component of SLE and is a prime target for the development of new agents for a wide range of lupus severity, including advanced disease. Although many current drugs appear to modify B cell function, the advent of new, targeted therapies offers the hope of improved efficacy and a better long-term tolerability profile.</p></abstract></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>The B cell in systemic lupus erythaematosus: a rational target for more effective therapy</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>The B cell in systemic lupus erythaematosus: a rational target for more effective therapy</title></titleInfo><name type="personal"><namePart type="given">C B</namePart><namePart type="family">Driver</namePart><affiliation>Cedars-Sinai Medical Center, Los Angeles, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Ishimori</namePart><affiliation>Cedars-Sinai Medical Center, Los Angeles, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M H</namePart><namePart type="family">Weisman</namePart><affiliation>Cedars-Sinai Medical Center, Los Angeles, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><dateIssued encoding="w3cdtf">2008-10</dateIssued><dateCreated encoding="w3cdtf">2007-08-24</dateCreated><copyrightDate encoding="w3cdtf">2008</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Current treatment options for systemic lupus erythaematosus (SLE) are diverse and poorly defined, and aggressive therapy can be associated with serious toxicity and tolerability issues. There is, therefore, a need for new and improved treatments to be studied thoroughly in well-designed controlled trials. B Cell dysfunction has emerged as a key pathophysiological component of SLE and is a prime target for the development of new agents for a wide range of lupus severity, including advanced disease. Although many current drugs appear to modify B cell function, the advent of new, targeted therapies offers the hope of improved efficacy and a better long-term tolerability profile.</abstract><relatedItem type="host"><titleInfo><title>Annals of the Rheumatic Diseases</title></titleInfo><titleInfo type="abbreviated"><title>Ann Rheum Dis</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0003-4967</identifier><identifier type="eISSN">1468-2060</identifier><identifier type="PublisherID">ard</identifier><identifier type="PublisherID-hwp">annrheumdis</identifier><identifier type="PublisherID-nlm-ta">Ann Rheum Dis</identifier><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><detail type="issue"><caption>no.</caption><number>10</number></detail><extent unit="pages"><start>1374</start></extent></part></relatedItem><identifier type="istex">ECFC78EBE021338B8A8F536C827BFF4FCD7B5CBE</identifier><identifier type="ark">ark:/67375/NVC-1M8N6Z0Q-5</identifier><identifier type="DOI">10.1136/ard.2007.076745</identifier><identifier type="href">annrheumdis-67-1374.pdf</identifier><identifier type="ArticleID">ar76745</identifier><identifier type="PMID">17720723</identifier><identifier type="local">annrheumdis;67/10/1374</identifier><accessCondition type="use and reproduction" contentType="copyright">2008 BMJ Publishing Group and European League Against Rheumatism</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</recordContentSource><recordOrigin>2008 BMJ Publishing Group and European League Against Rheumatism</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-1M8N6Z0Q-5/record.json</uri></json:item></metadata><annexes><json:item><extension>jpeg</extension><original>true</original><mimetype>image/jpeg</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-1M8N6Z0Q-5/annexes.jpeg</uri></json:item></annexes><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001200 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001200 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:ECFC78EBE021338B8A8F536C827BFF4FCD7B5CBE
|texte= The B cell in systemic lupus erythaematosus: a rational target for more effective therapy
}}
| This area was generated with Dilib version V0.6.33. |  |